Dr. Richard Angell is the head of the Drug Discovery Group in the Translational Research Office at University College London (UCL). He completed his PhD in Synthetic Organic Chemistry at the University of Reading before taking a position at Glaxo in 1992, where he worked on projects directed towards novel treatments for viral infections (CMV) and asthma. He was a member of the EGFr/erbB2 project team that discovered lapatinib (Tykerb) for breast cancer and the p38 rheumatoid arthritis team that discovered losmapimod. In 2001 he joined Arrow Therapeutics Ltd where he was Head of Discovery, leading a multi-disciplinary team focused on the early stage antiviral drug discovery projects. The team delivered three preclinical drug candidates starting from Hits-to-Leads screening efforts. He has experience leading projects in anticancer, antibacterial, antiviral and anti-inflammatory disease areas. He joined the Translational Research Office of University College London (UCL) in November 2012 where his role has involved helping PIs at UCL build data packages suitable for translational funding application, particularly focusing on small molecule drug discovery. His research interests include small molecule drug discovery, compound design, molecular property profiling, the design and synthesis of small molecule libraries, hit identification strategies and finding starting points for new small molecule Hits-to-Leads drug discovery projects.